MedTrace Logo

Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder

NCT04466345 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-10-02

No results posted yet for this study

Summary

This study will examine whether semaglutide may improve cognitive function in individuals with major depressive disorder (MDD).

Conditions

Interventions

BIOLOGICAL

Semaglutide

3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks

BIOLOGICAL

Placebo

Semaglutide placebo capsules

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Rodrigo B. Mansur, MD, PhD · University Health Network, Toronto

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-06
Primary Completion
2024-12-27
Completion
2024-12-27
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04466345 on ClinicalTrials.gov